Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RA1115-B1 is a topical ophthalmic eye drop formulation being developed by Suzhou Raymon Pharmaceuticals for the treatment of wet age-related macular degeneration (wAMD). It is designed to provide a non-invasive alternative to the current standard of care, which involves intravitreal injections of anti-VEGF agents. Phase 1 clinical trials in China were completed in August 2023, demonstrating the feasibility of the drug's penetration to the fundus when administered topically. While the specific molecular target and mechanism of action have not been disclosed, the drug represents a significant innovation in the delivery of therapies for retinal diseases, potentially improving patient compliance and reducing the risks associated with invasive ocular injections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RA1115-B1.